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Characterization and toxicity of citral incorporated with nanostructured lipid carrier 
ABSTRACT 
The nanoparticle as a cancer drug delivery vehicle is rapidly under investigation due to its 
promising applicability as a novel drug delivery system for anticancer agents. This study 
describes the development, characterization and toxicity studies of a nanostructured lipid 
carrier (NLC) system for citral. Citral was loaded into the NLC using high pressure 
homogenization methods. The characterizations of NLCcitral were then determined through 
various methods. Based on Transmission Electron Microscope (TEM) analysis, NLC-Citral 
showed a spherical shape with an average diameter size of 54.12 ± 0.30 nm and a polydipersity 
index of 0.224 ± 0.005. The zeta potential of NLC-Citral was −12.73 ± 0.34 mV with an 
entrapment efficiency of 98.9 ± 0.124%, and drug loading of 9.84 ± 0.041%. Safety profile of 
the formulation was examined via in vitro and in vivo routes to study its effects toward normal 
cells. NLC-Citral exhibited no toxic effects towards the proliferation of mice splenocytes. 
Moreover, no mortality and toxic signs were observed in the treated groups after 28 days of 
treatment. There were also no significant alterations in serum biochemical analysis for all 
treatments. Increase in immunomodulatory effects of treated NLC-Citral and Citral groups was 
verified from the increase in CD4/CD3 and CD8/CD3 T cell population in both NLC-citral and 
citral treated splenocytes. This study suggests that NLC is a promising drug delivery system 
for citral as it has the potential in sustaining drug release without inducing any toxicity. 
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